Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could carbon monoxide help Parkinson's? small trial begins

NCT ID NCT07005180

Recruiting now Symptom relief Sponsor: Hillhurst Biopharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2a trial tests an oral liquid containing low-dose carbon monoxide (HBI-002) in 36 people with Parkinson's disease. Participants take it daily for 14 days to see if it is safe and tolerable. The study is randomized and placebo-controlled, meaning some get the drug and some get a dummy liquid. It is too early to know if it helps symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low-dose carbon monoxide liquid (HBI-002)
What this could lead to
If it works, this could point toward a new way to ease symptoms or slow Parkinson's disease progression.
What could go wrong
This is a very early, small phase 2a trial focused on safety, not effectiveness. Carbon monoxide is toxic at high doses, so even low doses carry unknown risks. Results may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Quest Research Institute

    RECRUITING

    Farmington Hills, Michigan, 48334, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.